TenderlineUK
Procurement Intelligence
Search
Find a TenderAwarded
Published 2 Aug 2024, 13:44 BST

Official UK procurement notice

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

Official notice

Authority: NHS England (Central government)·Consortium: 2 public authorities

Framework agreement6 lotsGoodsOpen procedure
Sectors: Medical Devices & Pharma (33) Delivery: UK
Framework ceiling (notional)£1,700,000,000total for 6 lots · framework ceiling, not attributable revenue
Submissions closed 13 Sept 2024awarded 19 Dec 2024
Lots 6see the lot list below
Framework period 2 yrs 9 moends 31 Dec 2027 · starts 1 Apr 2025

What is being bought6 lots · detail below

Published requirement description

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>The period of the framework is 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months.

CPV: Immunoglobulins

How this framework works

From the published notice
Bids received
6 bids received · 6 suppliers appointed
Framework period
2 yrs 9 mo from 1 Apr 2025

Lots and requirements (6)Procurement structure

6 lots · 5 with a published value

Every one of these 5 lots carries the same published figure, £1: it is the framework's maximum for the whole notice, not each lot's own budget, and no share per lot is published. The cards below say ceiling above rather than repeat it.

Lot #1Low and High Strength AlbuminCancelled 2 yrs 9 moceiling above

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins
Lot #25% Intravenous ImmunoglobulinAwarded 2 yrs 9 moceiling above

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins
Lot #310% Intravenous ImmunoglobulinAwarded 2 yrs 9 moceiling above

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins
Lot #4Subcutaneous ImmunoglobulinAwarded 2 yrs 9 moLot estimate not published

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins
Lot #5Facilitated Subcutaneous ImmunoglobulinAwarded 2 yrs 9 moceiling above

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins
Lot #6Anti-D ImmunoglobulinAwarded 2 yrs 9 moceiling above

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Contract period: 1 Apr 2025 – 31 Dec 2027 (2 yrs 9 mo)
Delivery: UK · ITT lists participating authorities
Variant bids: not allowed
33651520 Immunoglobulins

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
What this means for your bid
  • “NHS Framework Agreement for Human Albumin & Normal and Anti-D…” is a framework: the contest is a place on its panel, not a single contract.

Procedure terms & legal framework

From the official record · publisher note attached
Procedure method
Open procedure
Legal basis
CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category
Goods
Notice status
Awarded
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type
Competitive procedure
GPA / WTO covered
Unspecified in notice
Recurring procurement
No (one-off requirement)
First published
2 Aug 2024, 13:44 BST
Last source update
20 Jan 2025, 15:25 GMT
Award evaluation window
13 Sept 2024 – …
Authority reference
CM/PHS/23/5703
FTS notice number
2025/S 000-001899
Classification (CPV)
Immunoglobulins
Delivery area
UK
Official registry OCID
ocds-h6vhtk-048730 Find a Tender
Contract terms
Electronic trading
e-invoicing allowed · electronic ordering · electronic payment

Publisher note: Out of the awarded suppliers, they were either awarded a committed market share or designated as reserve status with no committed market share. Further information on committed or reserve status by Lot is shown below:<br/><br/>Lot 1<br/>Awarded Supplier - CSL, Grifols<br/>Reserve Supplier - Octapharma<br/><br/>Lot 2<br/>Awarded Supplier - Octapharma<br/>Reserve Supplier - Grifols, Takeda<br/><br/>Lot 3<br/>Awarded Supplier - Grifols, Octapharma, Takeda<br/>Reserve Supplier - BPL, CSL, LFB<br/><br/>Lot 4<br/>Awarded Supplier - Grifols, Octapharma, Takeda<br/>Reserve Supplier - CSL<br/><br/>Lot 5<br/>Awarded Supplier - Takeda<br/>Reserve Supplier – N/A<br/><br/>Lot 6 <br/>Awarded Supplier - CSL<br/>Reserve Supplier - BPL

How it was run

Official notice
Run through: Atamis legacy domain (health-family.force.com) · Who buys & how to bid on Atamis
Supplier login requiredLanguage: EN
Access & registration note: Legacy Salesforce domain still used in notices — use the current Atamis portal · this portal address is a legacy domain; the operator has migrated

Tender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗

Appointment period ends
13 Sept 2024, 13:00 BST
Submission channel
{"electronicSubmission","written"}
Accepted languages
en
Bid validity
180 days from the deadline
Bids opened
13 Sept 2024, 13:00 BST
Detailed submission instructions & authority contactsFrom official release

health-family.force.com/s/Welcome ↗

Timeline

13 Sept 2024 → 1 Apr 2025 · 4 dates
  1. Admission / appointment period endsperiod end, not a bid countdown
    13 Sept 2024, 13:00 BST
  2. Bids opened
    13 Sept 2024, 13:00 BST
  3. Notice published
    20 Jan 2025, 15:25 GMT
  4. Contract starts
    1 Apr 2025, 00:00 BST

Notice history

2 events · 2 releases on Find a Tender · since 20 Jan 2025
  1. Status changed to complete
    20 Jan 2025, 15:25 GMT
  2. Buyer details updated
    20 Jan 2025, 15:25 GMT

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Suppliers appointed 6admitted to the panel · see the list ↓
Bids received 6
Contracts signed 19latest 19 Dec 2024

19 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.

Contracts

All 19 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

  • NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

    Signed
    19 Dec 2024
    Value
    ceiling above
    Period
    … – 31 Dec 2027
    Status
    active

Bid statistics published by the authority

LotBidsSMEVCSEValid bid range
2 · 5% Intravenous Immunoglobulin6bids · 6 electronic0——
3 · 10% Intravenous Immunoglobulin6bids · 6 electronic0——
4 · Subcutaneous Immunoglobulin6bids · 6 electronic0——
5 · Facilitated Subcutaneous Immunoglobulin6bids · 6 electronic0——
6 · Anti-D Immunoglobulin6bids · 6 electronic0——
Whole notice6bids · 6 electronic0——

Contracting authority & participating public bodies

2 public bodies on the notice

NHS England

Contracting authorityCentral GovernmentMinistry or any other national or federal authority, including their regional or local subdivisionsHealth 7-8 Wellington Place, Leeds, UK, LS1 4APContact name, email

Dispute resolution & review bodies

  • The High CourtReview body London

Framework contractors & participating bidders

7 commercial parties on the notice
  • BIO PRODUCTS LABORATORY LIMITEDFramework contractor07343036 C/O Bio Products Laboratory, Dagger Lane, Elstree, Hertfordshire, WD6 3BX, Elstree, UK, WD6 3BX
  • BIO PRODUCTS LABORATORY LIMITEDFramework contractor07343036 C/O Bio Products Laboratory, Dagger Lane, Elstree, Hertfordshire, WD6 3BX, ELSTREEE, UK, WD6 3BX
  • CSL BEHRING UK LIMITEDFramework contractor01622483 4 Milton Road Haywards Heath West Sussex, Haywards Heath, UK, RH16 1AH
  • Grifols UK (Diagnostics)Framework contractor01456099 6th Floor One London Wall, London, EC2Y 5EB, LONDON, UK, EC2Y 5EB
  • LFB BIOMEDICAMENTSFramework contractor491371167 3 AVENUE DES TROPIQUES 91940 LES ULIS FRANCE, Les Ulis, FR, 91958Contact phone
  • Octapharma LimitedFramework contractor02372699 Octapharma Ltd, 32 Shudehill, Manchester, M4 1EZ, Manchester, UK, M4 1EZ
  • Takeda UK LimitedFramework contractor03362860 1 Kingdom Street, LONDON, UK, W2 6BDContact email

Official documents & specifications (1)

Official links; attachments are not copied

Tender pack and attachments

  • Economic and financial selection criteriatenderEconomic and financial selection criteria